Selected research
Market Structure
Global Sunitinib Malate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Sunitinib Malate market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Sunitinib Malate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Sunitinib Malate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Sunitinib Malate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Sunitinib Malate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Sunitinib Malate include CSPC, Qilu Pharmaceutical, Nanjing First Pharmaceutical Co., Ltd., Hansoh Pharma, Pfizer Sutent, Topcare pharmaceutical Co., Ltd, Target Molecule Corp. and J&K Scientific, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Sunitinib Malate market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Sunitinib Malate and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Sunitinib Malate sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Sunitinib Malate market size, projected growth trends, production technologies, key applications, and end-use industries.
Sunitinib Malate Segment by Company
CSPC
Qilu Pharmaceutical
Nanjing First Pharmaceutical Co., Ltd.
Hansoh Pharma
Pfizer Sutent
Topcare pharmaceutical Co., Ltd
Target Molecule Corp.
J&K Scientific
Sunitinib Malate Segment by Type
12.5mg
37.5mg
50mg
Sunitinib Malate Segment by Application
Advanced Kidney Cancer
GIST (Gastrointestinal Stromal Tumor)
Pancreatic Neuroendocrine Tumors
Sunitinib Malate Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sunitinib Malate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sunitinib Malate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sunitinib Malate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Sunitinib Malate market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sunitinib Malate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Sunitinib Malate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Sunitinib Malate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 12.5mg
- 37.5mg
- 50mg
Applications
- Advanced Kidney Cancer
- GIST (Gastrointestinal Stromal Tumor)
- Pancreatic Neuroendocrine Tumors
Companies covered
- CSPC
- Qilu Pharmaceutical
- Nanjing First Pharmaceutical Co., Ltd.
- Hansoh Pharma
- Pfizer Sutent
- Topcare pharmaceutical Co., Ltd
- Target Molecule Corp.
- J&K Scientific
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Sunitinib Malate Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Sunitinib Malate Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Sunitinib Malate Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Sunitinib Malate Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Sunitinib Malate Market Dynamics
- 2.1 Sunitinib Malate Industry Trends
- 2.2 Sunitinib Malate Industry Drivers
- 2.3 Sunitinib Malate Industry Opportunities and Challenges
- 2.4 Sunitinib Malate Industry Restraints
3 Sunitinib Malate Market by Manufacturers
- 3.1 Global Sunitinib Malate Revenue by Manufacturers (2021-2026)
- 3.2 Global Sunitinib Malate Sales by Manufacturers (2021-2026)
- 3.3 Global Sunitinib Malate Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Sunitinib Malate Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Sunitinib Malate Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Sunitinib Malate Manufacturers, Product Type & Application
- 3.7 Global Sunitinib Malate Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Sunitinib Malate Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Sunitinib Malate Players Market Share by Revenue in 2025
- 3.8.3 2025 Sunitinib Malate Tier 1, Tier 2, and Tier 3
4 Sunitinib Malate Market by Type
- 4.1 Sunitinib Malate Type Introduction
- 4.1.1 12.5mg
- 4.1.2 37.5mg
- 4.1.3 50mg
- 4.2 Global Sunitinib Malate Sales by Type
- 4.2.1 Global Sunitinib Malate Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Sunitinib Malate Sales by Type (2021-2032)
- 4.2.3 Global Sunitinib Malate Sales Market Share by Type (2021-2032)
- 4.3 Global Sunitinib Malate Revenue by Type
- 4.3.1 Global Sunitinib Malate Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Sunitinib Malate Revenue by Type (2021-2032)
- 4.3.3 Global Sunitinib Malate Revenue Market Share by Type (2021-2032)
5 Sunitinib Malate Market by Application
- 5.1 Sunitinib Malate Application Introduction
- 5.1.1 Advanced Kidney Cancer
- 5.1.2 GIST (Gastrointestinal Stromal Tumor)
- 5.1.3 Pancreatic Neuroendocrine Tumors
- 5.2 Global Sunitinib Malate Sales by Application
- 5.2.1 Global Sunitinib Malate Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Sunitinib Malate Sales by Application (2021-2032)
- 5.2.3 Global Sunitinib Malate Sales Market Share by Application (2021-2032)
- 5.3 Global Sunitinib Malate Revenue by Application
- 5.3.1 Global Sunitinib Malate Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Sunitinib Malate Revenue by Application (2021-2032)
- 5.3.3 Global Sunitinib Malate Revenue Market Share by Application (2021-2032)
6 Global Sunitinib Malate Sales by Region
- 6.1 Global Sunitinib Malate Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Sunitinib Malate Sales by Region (2021-2032)
- 6.2.1 Global Sunitinib Malate Sales by Region (2021-2026)
- 6.2.2 Global Sunitinib Malate Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Sunitinib Malate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Sunitinib Malate Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Sunitinib Malate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Sunitinib Malate Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Sunitinib Malate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Sunitinib Malate Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Sunitinib Malate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Sunitinib Malate Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Sunitinib Malate Revenue by Region
- 7.1 Global Sunitinib Malate Revenue by Region
- 7.1.1 Global Sunitinib Malate Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Sunitinib Malate Revenue by Region (2021-2026)
- 7.1.3 Global Sunitinib Malate Revenue by Region (2027-2032)
- 7.1.4 Global Sunitinib Malate Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Sunitinib Malate Revenue (2021-2032)
- 7.2.2 North America Sunitinib Malate Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Sunitinib Malate Revenue (2021-2032)
- 7.3.2 Europe Sunitinib Malate Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Sunitinib Malate Revenue (2021-2032)
- 7.4.2 Asia-Pacific Sunitinib Malate Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Sunitinib Malate Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Sunitinib Malate Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 CSPC
- 8.1.1 CSPC Company Information
- 8.1.2 CSPC Business Overview
- 8.1.3 CSPC Sunitinib Malate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 CSPC Sunitinib Malate Product Portfolio
- 8.1.5 CSPC Recent Developments
- 8.2 Qilu Pharmaceutical
- 8.2.1 Qilu Pharmaceutical Company Information
- 8.2.2 Qilu Pharmaceutical Business Overview
- 8.2.3 Qilu Pharmaceutical Sunitinib Malate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Qilu Pharmaceutical Sunitinib Malate Product Portfolio
- 8.2.5 Qilu Pharmaceutical Recent Developments
- 8.3 Nanjing First Pharmaceutical Co., Ltd.
- 8.3.1 Nanjing First Pharmaceutical Co., Ltd. Company Information
- 8.3.2 Nanjing First Pharmaceutical Co., Ltd. Business Overview
- 8.3.3 Nanjing First Pharmaceutical Co., Ltd. Sunitinib Malate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Nanjing First Pharmaceutical Co., Ltd. Sunitinib Malate Product Portfolio
- 8.3.5 Nanjing First Pharmaceutical Co., Ltd. Recent Developments
- 8.4 Hansoh Pharma
- 8.4.1 Hansoh Pharma Company Information
- 8.4.2 Hansoh Pharma Business Overview
- 8.4.3 Hansoh Pharma Sunitinib Malate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Hansoh Pharma Sunitinib Malate Product Portfolio
- 8.4.5 Hansoh Pharma Recent Developments
- 8.5 Pfizer Sutent
- 8.5.1 Pfizer Sutent Company Information
- 8.5.2 Pfizer Sutent Business Overview
- 8.5.3 Pfizer Sutent Sunitinib Malate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Pfizer Sutent Sunitinib Malate Product Portfolio
- 8.5.5 Pfizer Sutent Recent Developments
- 8.6 Topcare pharmaceutical Co., Ltd
- 8.6.1 Topcare pharmaceutical Co., Ltd Company Information
- 8.6.2 Topcare pharmaceutical Co., Ltd Business Overview
- 8.6.3 Topcare pharmaceutical Co., Ltd Sunitinib Malate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Topcare pharmaceutical Co., Ltd Sunitinib Malate Product Portfolio
- 8.6.5 Topcare pharmaceutical Co., Ltd Recent Developments
- 8.7 Target Molecule Corp.
- 8.7.1 Target Molecule Corp. Company Information
- 8.7.2 Target Molecule Corp. Business Overview
- 8.7.3 Target Molecule Corp. Sunitinib Malate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Target Molecule Corp. Sunitinib Malate Product Portfolio
- 8.7.5 Target Molecule Corp. Recent Developments
- 8.8 J&K Scientific
- 8.8.1 J&K Scientific Company Information
- 8.8.2 J&K Scientific Business Overview
- 8.8.3 J&K Scientific Sunitinib Malate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 J&K Scientific Sunitinib Malate Product Portfolio
- 8.8.5 J&K Scientific Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Sunitinib Malate Value Chain Analysis
- 9.1.1 Sunitinib Malate Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Sunitinib Malate Production Mode & Process
- 9.2 Sunitinib Malate Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Sunitinib Malate Distributors
- 9.2.3 Sunitinib Malate Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst